Aptahem’s development portfolio comprises aptamers, so-called synthetic (artificial) nucleic acid polymers. An aptamer consists either of single-string DNA or RNA (ssDNA or ssRNA). These molecules will bind specifically with selected targets, including proteins and peptides with high affinity and specificity.

Aptahem’s aptamers can be compared to small antibodies, and some aptamers are stereoselective. Aptamers show several substantial advantages over antibodies:

Aptahem’s aptamers are synthetically produced, ie no biologicals are included in the manufacturing – hence they can be reproduced cheaper, easier and with higher precision

  • They are 6-10 times smaller which makes it easier for them to penetrate membrane and attack antigens that antibodies would miss
  • Aptamers are easier to synthesize and chemically modify
  • Aptamers have lower immunogenicity, which could result in less side effects in patient

These advantages compared to antibodies become particularly significant as treatments are more personlized and case-specific. Aptahem’s RNA aptamers have specifically shown to be very safe, i e with low toxicity, and have at the same time indicated a strong effect on coagulation, inflammation and tissue repair. Also, they do not seem to go into the cell, which Aptahem considers an advantage as effects of the cell nucleus might lead to unwanted immunological effects.